ANL · NASDAQ · Biotechnology

Adlai Nortye (ADR) (ANL)

Develops clinical-stage cancer therapies targeting RAS pathways and immune responses.

$16.60
After hours+0.04 (+0.24%)
At close$16.56(+6.36%)